Judith Ann Clements

List of Publications by Year
in descending order

151 papers	10,077 citations	36303 51 h-index	38395 95 g-index
158 all docs	158 docs citations	158 times ranked	14124 citing authors

#	Article	IF	Citations
1	Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nature Reviews Cancer, 2022, 22, 223-238.	28.4	38
2	A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. Journal of the American Chemical Society, 2021, 143, 8911-8924.	13.7	14
3	In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Science Advances, 2021, 7, .	10.3	20
4	KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer. Cancers, 2020, 12, 3501.	3.7	5
5	Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts. Biomaterials, 2019, 220, 119402.	11.4	28
6	Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome. Molecular and Cellular Proteomics, 2019, 18, 818a-836.	3.8	16
7	Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment. Bone Research, 2019, 7, 13.	11.4	27
8	MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer. Clinical Chemistry, 2019, 65, 771-780.	3.2	15
9	Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function. Clinical Chemistry, 2019, 65, e1-e9.	3.2	17
10	Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. British Journal of Cancer, 2018, 119, 1-9.	6.4	27
11	Kallikreinâ€related peptidase 4 induces cancerâ€associated fibroblast features in prostateâ€derived stromal cells. Molecular Oncology, 2017, 11, 1307-1329.	4.6	17
12	Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy. Expert Review of Proteomics, 2017, 14, 1119-1130.	3.0	1
13	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	6.4	7
14	Mass spectrometry-based determination of Kallikrein-related peptidase 7 (KLK7) cleavage preferences and subsite dependency. Scientific Reports, 2017, 7, 6789.	3.3	6
15	Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum. Journal of Investigative Dermatology, 2017, 137, 430-439.	0.7	50
16	Enter the Dragon: The Dynamic and Multifunctional Evolution of Anguimorpha Lizard Venoms. Toxins, 2017, 9, 242.	3.4	37
17	Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases. American Journal of Cancer Research, 2017, 7, 2257-2274.	1.4	10
18	MicroRNA Theranostics in Prostate Cancer Precision Medicine. Clinical Chemistry, 2016, 62, 1318-1333.	3.2	47

#	Article	IF	Citations
19	Prostate Cancer-Associated Kallikrein-Related Peptidase 4 Activates Matrix Metalloproteinase-1 and Thrombospondin-1. Journal of Proteome Research, 2016, 15, 2466-2478.	3.7	30
20	Lycopene's Effects on Cancer Cell Functions within Monolayer and Spheroid Cultures. Nutrition and Cancer, 2016, 68, 350-363.	2.0	7
21	Assays for Qualification and Quality Stratification of Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen Science Working Group. Biopreservation and Biobanking, 2016, 14, 398-409.	1.0	40
22	In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B. Biological Chemistry, 2016, 397, 1299-1305.	2.5	8
23	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
24	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50
25	A computational analysis of the genetic and transcript diversity at the kallikrein locus. Biological Chemistry, 2016, 397, 1307-1313.	2.5	3
26	Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors. Biological Chemistry, 2016, 397, 1237-1249.	2.5	28
27	Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 29-39.	6.1	71
28	Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. Oncotarget, 2016, 7, 2572-2584.	1.8	21
29	Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. Oncotarget, 2016, 7, 4939-4948.	1.8	24
30	Fusion transcript loci share many genomic features with non-fusion loci. BMC Genomics, 2015, 16, 1021.	2.8	16
31	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	2.3	54
32	Tissue engineered humanized bone supports human hematopoiesisÂinÂvivo. Biomaterials, 2015, 61, 103-114.	11.4	62
33	A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocrine-Related Cancer, 2015, 22, 265-276.	3.1	56
34	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	9.4	56
35	Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population. Quality of Life Research, 2015, 24, 2183-2193.	3.1	3
36	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56

#	Article	IF	Citations
37	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	2.9	67
38	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	2.5	27
39	Transforming the Future of Treatment for Ovarian Cancer. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	0
40	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	3.5	34
41	Proteomic and other analyses to determine the functional consequences of deregulated kallikreinâ€related peptidase (<scp>KLK</scp>) expression in prostate and ovarian cancer. Proteomics - Clinical Applications, 2014, 8, 403-415.	1.6	10
42	Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer. Biological Chemistry, 2014, 395, 1127-1132.	2.5	17
43	Single Nucleotide Polymorphisms (SNPs). , 2014, , 55-80.		2
44	Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clinical and Experimental Metastasis, 2014, 31, 135-147.	3.3	47
45	A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clinical and Experimental Metastasis, 2014, 31, 435-446.	3.3	39
46	Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone, 2014, 63, 121-131.	2.9	58
47	Secretome and degradome profiling shows that Kallikreinâ€related peptidases 4, 5, 6, and 7 induce TGFÎ²â€1 signaling in ovarian cancer cells. Molecular Oncology, 2014, 8, 68-82.	4.6	51
48	Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases. Biological Chemistry, 2014, 395, 977-990.	2.5	13
49	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
50	Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses. Advanced Drug Delivery Reviews, 2014, 79-80, 193-213.	13.7	45
51	Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials, 2014, 35, 4108-4115.	11.4	95
52	3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer. PLoS ONE, 2014, 9, e111029.	2.5	79
53	Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2014, 25, 269-81.	0.7	14
54	A bioengineered 3D ovarian cancer model for the assessment ofÂpeptidaseâ€“mediated enhancement of spheroid growth andÂintraperitoneal spread. Biomaterials, 2013, 34, 7389-7400.	11.4	53

#	Article	IF	Citations
55	Candidate gene association studies: a comprehensive guide to useful in silicotools. BMC Genetics, 2013, 14, 39.	2.7	115
56	The Human Tissue Kallikrein and Kallikrein-related Peptidase Family. , 2013, , 2747-2756.		1
57	Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer and Metastasis Reviews, 2013, 32, 129-145.	5.9	41
58	Identification of Evidence-Based Biospecimen Quality-Control Tools. Journal of Molecular Diagnostics, 2013, 15, 3-16.	2.8	79
59	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
60	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 635-643.	1.6	30
61	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
62	The Potential Role of Lycopene for the Prevention and Therapy of Prostate Cancer: From Molecular Mechanisms to Clinical Evidence. International Journal of Molecular Sciences, 2013, 14, 14620-14646.	4.1	146
63	Delineating breast cancer cell interactions with engineered bone microenvironments. Journal of Bone and Mineral Research, 2013, 28, 1399-1411.	2.8	33
64	Paclitaxel Resistance and Multicellular Spheroid Formation Are Induced by Kallikrein-Related Peptidase 4 in Serous Ovarian Cancer Cells in an Ascites Mimicking Microenvironment. PLoS ONE, 2013, 8, e57056.	2.5	47
65	Breast Cancer Cells Induce Osteolytic Bone Lesions In vivo through a Reduction in Osteoblast Activity in Mice. PLoS ONE, 2013, 8, e68103.	2.5	17
66	Kallikrein-related Peptidase 15 (Prostinogen). , 2013, , 2814-2817.		0
67	Expression of PTRF in PC-3 Cells Modulates Cholesterol Dynamics and the Actin Cytoskeleton Impacting Secretion Pathways. Molecular and Cellular Proteomics, 2012, 11, M111.012245.	3.8	59
68	The Cell Surface Glycoprotein CUB Domain-containing Protein 1 (CDCP1) Contributes to Epidermal Growth Factor Receptor-mediated Cell Migration. Journal of Biological Chemistry, 2012, 287, 9792-9803.	3.4	36
69	The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness. Biological Chemistry, 2012, 393, 403-412.	2.5	15
70	Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases. Biological Chemistry, 2012, 393, 1365-1390.	2.5	24
71	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecologic Oncology, 2012, 127, 569-578.	1.4	33
72	Standard Preanalytical Coding for Biospecimens: Review and Implementation of the Sample PREanalytical Code (SPREC). Biopreservation and Biobanking, 2012, 10, 366-374.	1.0	146

#	Article	IF	Citations
73	Selective Cleavage of Human Sex Hormone-Binding Globulin by Kallikrein-Related Peptidases and Effects on Androgen Action in LNCaP Prostate Cancer Cells. Endocrinology, 2012, 153, 3179-3189.	2.8	11
74	Long Terminal Repeats Act as Androgen-Responsive Enhancers for the PSA-Kallikrein Locus. Endocrinology, 2012, 153, 3199-3210.	2.8	17
75	Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology, Immunotherapy, 2012, 61, 169-179.	4.2	21
76	Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment. PLoS ONE, 2012, 7, e40217.	2.5	75
77	Genetic Association of the KLK4 Locus with Risk of Prostate Cancer. PLoS ONE, 2012, 7, e44520.	2.5	18
78	A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer, 2011, 11, 119.	2.6	20
79	Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate, 2011, 71, 1198-1209.	2.3	93
80	Correlation of the expression of human kallikreinâ€related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma. Head and Neck, 2011, 33, 566-572.	2.0	17
81	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	21.4	265
82	Kallikrein-Related Peptidase 3(KLK3/PSA) Single Nucleotide Polymorphisms and Ovarian Cancer Survival. Twin Research and Human Genetics, 2011, 14, 323-327.	0.6	11
83	A Replication Study Examining Novel Common Single Nucleotide Polymorphisms Identified Through a Prostate Cancer Genome-wide Association Study in a Japanese Population. American Journal of Epidemiology, 2011, 174, 1391-1395.	3.4	14
84	Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data. PLoS ONE, 2011, 6, e26527.	2.5	14
85	Kallikrein-Related Peptidase 10 (KLK10) Expression and Single Nucleotide Polymorphisms in Ovarian Cancer Survival. International Journal of Gynecological Cancer, 2010, 20, 529-536.	2.5	18
86	Bioengineered 3D platform to explore cellâ€“ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials, 2010, 31, 8494-8506.	11.4	533
87	Can tissue engineering concepts advance tumor biology research?. Trends in Biotechnology, 2010, 28, 125-133.	9.3	208
88	Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials, 2010, 31, 7928-7936.	11.4	101
89	A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells. Rna, 2010, 16, 1156-1166.	3.5	36
90	Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 2010, 391, 461-6.	2.5	8

#	Article	IF	Citations
91	Kallikrein-Related Peptidase 7 Promotes Multicellular Aggregation via the Î±5Î²1 Integrin Pathway and Paclitaxel Chemoresistance in Serous Epithelial Ovarian Carcinoma. Cancer Research, 2010, 70, 2624-2633.	0.9	82
92	Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus. Endocrine Reviews, 2010, 31, 407-446.	20.1	214
93	Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1755-1765.	2.5	13
94	Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis, 2010, 6, 181-188.	1.2	69
95	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2611-2622.	2.5	145
96	The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2352-2365.	2.5	18
97	Direct Progesterone Receptor and Indirect Androgen Receptor Interactions with the Kallikrein-Related Peptidase 4 Gene Promoter in Breast and Prostate Cancer. Molecular Cancer Research, 2009, 7, 129-141.	3.4	26
98	Translating tissue engineering technology platforms into cancer research. Journal of Cellular and Molecular Medicine, 2009, 13, 1417-1427.	3.6	122
99	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	21.4	389
100	Substrate-Guided Design of a Potent and Selective Kallikrein-Related Peptidase Inhibitor for Kallikrein 4. Chemistry and Biology, 2009, 16, 633-643.	6.0	109
101	A novel transcript from the KLKP1 gene is androgen regulated, downâ€regulated during prostate cancer progression and encodes the first nonâ€serine protease identified from the human kallikrein gene locus. Prostate, 2008, 68, 381-399.	2.3	23
102	Tissue-specific promoter utilisation of the kallikrein-related peptidase genes,KLK5andKLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biological Chemistry, 2008, 389, 99-109.	2.5	17
103	Reflections on the tissue kallikrein and kallikrein-related peptidase family â€“ from mice to men â€“ what have we learnt in the last two decades?. Biological Chemistry, 2008, 389, 1447-1454.	2.5	22
104	Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs). Journal of Biological Chemistry, 2008, 283, 12293-12304.	3.4	122
105	Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological Chemistry, 2008, 389, 653-668.	2.5	38
106	Seminal Fluid Characterization for Male Fertility and Prostate Cancer: Kallikrein-Related Serine Proteases and Whole Proteome Approaches. Seminars in Thrombosis and Hemostasis, 2007, 33, 087-099.	2.7	56
107	Epithelial-Mesenchymal Transition in Prostate Cancer and the Potential Role of Kallikrein Serine Proteases. Cells Tissues Organs, 2007, 185, 111-115.	2.3	30
108	Epithelialâ€”mesenchymal and mesenchymalâ€”epithelial transitions in carcinoma progression. Journal of Cellular Physiology, 2007, 213, 374-383.	4.1	957

#	Article	IF	Citations
109	Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate, 2007, 67, 348-360.	2.3	50
110	Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU International, 2007, 99, 735-742.	2.5	30
111	Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?. Biological Chemistry, 2006, 387, 697-705.	2.5	36
112	PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis, 2006, 28, 1032-1039.	2.8	54
113	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biological Chemistry, 2006, 387, 637-41.	2.5	123
114	The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biological Chemistry, 2006, 387, 707-14.	2.5	32
115	The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers. Critical Reviews in Clinical Laboratory Sciences, 2004, 41, 265-312.	6.1	198
116	Expression analysis of ?-catenin and prostate-specific membrane antigen: Their potential as diagnostic markers for prostate cancer. International Journal of Cancer, 2002, 100, 228-237.	5.1	111
117	Identification and Characterization of KLK14, a Novel Kallikrein Serine Protease Gene Located on Human Chromosome 19q13.4 and Expressed in Prostate and Skeletal Muscle. Genomics, 2001, 73, 117-122.	2.9	56
118	TTYH2, a Human Homologue of the Drosophila melanogaster Gene tweety, Is Located on 17q24 and Upregulated in Renal Cell Carcinoma. Genomics, 2001, 77, 200-207.	2.9	40
119	Type II Transmembrane Serine Proteases. Journal of Biological Chemistry, 2001, 276, 857-860.	3.4	317
120	Characterization of a novel gene,STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Molecular Carcinogenesis, 2001, 32, 44-53.	2.7	68
121	The Expanded Human Kallikrein (KLK) Gene Family: Genomic Organisation, Tissue-Specific Expression and Potential Functions. Biological Chemistry, 2001, 382, 5-14.	2.5	126
122	Kallikrein 4 (KLK4), A New Member of the Human Kallikrein Gene Family Is Up-Regulated By Estrogen and Progesterone in the Human Endometrial Cancer Cell Line, KLE. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2323-2323.	3.6	13
123	Tissue-specific Expression Patterns and Fine Mapping of the Human Kallikrein (KLK) Locus on Proximal 19q13.4. Journal of Biological Chemistry, 2000, 275, 37397-37406.	3.4	125
124	Temporal and Tissue-Specific Expression of Kallikrein (Klk) Genes and Identification of a Novel Klk Messenger Ribonucleic Acid Transcript during Early Development in the Mouse1. Biology of Reproduction, 1999, 61, 621-628.	2.7	20
125	Localization of a New Prostate-specific Antigen-related Serine Protease Gene, KLK4 , Is Evidence for an Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3â€“13.4. Journal of Biological Chemistry, 1999, 274, 23210-23214.	3.4	90
126	The human tissue kallikreins (KLKs 1â€“3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. Immunopharmacology, 1999, 45, 83-88.	2.0	20

#	Article	IF	Citations
127	MOLECULAR DETECTION OF PROSTATE CELLS IN EJACULATE AND URETHRAL WASHINGS IN MEN WITH SUSPECTED PROSTATE CANCER. Journal of Urology, 1999, 161, 1337-1343.	0.4	32
128	ACTIVATION OF THE KALLIKREIN KININ SYSTEM IN INTERSTITIAL CYSTITIS. Journal of Urology, 1999, 162, 129-134.	0.4	27
129	KALLIKREINS AND KININS IN INFLAMMATORY-LIKE EVENTS IN THE REPRODUCTIVE TRACT. Pharmacological Research, 1997, 35, 537-540.	7.1	21
130	The Molecular Biology of the Kallikreins and their Roles in Inflammation. , 1997, , 71-97.		34
131	Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. Immunopharmacology, 1997, 36, 217-220.	2.0	30
132	The human kallikrein gene family: a diversity of expression and function. Molecular and Cellular Endocrinology, 1994, 99, C1-C6.	3.2	101
133	Oestrogen administration and the expression of the kallikrein gene family in the rat submandibular gland. The Journal of Steroid Biochemistry, 1990, 35, 55-60.	1.1	9
134	Glucocorticoid Regulation of Proopiomelanocortin Gene Expression in the Pituitary Gland of Hypothalamopituitary Intact and Hypothalamopituitary Disconnected Sheep. Neuroendocrinology, 1989, 50, 280-285.	2.5	31
135	Regulation of Follicle-Stimulating Hormone Î² and Common Î±-Subunit Messenger Ribonucleic Acid by Gonadotropin-Releasing Hormone and Estrogen in the Sheep Pituitary. Neuroendocrinology, 1989, 50, 321-326.	2.5	29
136	The Glandular Kallikrein Family of Enzymes: Tissue Specific Expression and Hormonal Regulation. Endocrine Reviews, 1989, 10, 393-419.	20.1	214
137	The Expression of the Kallikrein Gene Family in the Rat Pituitary: Oestrogen Effects and the Expression of an Additional Family Member in the Neurointermediate Lobe. Journal of Neuroendocrinology, 1989, 1, 198-203.	2.6	13
138	Gonadal steroids and anterior lobe dynorphin in the male rat. The Journal of Steroid Biochemistry, 1989, 32, 303-308.	1.1	5
139	Regulation of liver angiotensinogen mRNA by glucocorticoids and thyroxine. Molecular and Cellular Endocrinology, 1989, 61, 147-156.	3.2	23
140	Kallikrein gene expression in estrogen-induced pituitary tumors. Molecular and Cellular Endocrinology, 1988, 60, 225-232.	3.2	28
141	Post-Translational Processing of Pro-Opiomelanocortin in the Brattleboro (di/di) Rat Pituitary. Neuroendocrinology, 1988, 48, 603-610.	2.5	8
142	Concomitant Dopaminergic and Glucocorticoid Control of Pituitary Proopiomelanocortin Messenger Ribonucleic Acid and Î²-Endorphin Levels*. Endocrinology, 1987, 121, 1689-1696.	2.8	34
143	Inhibin a-subunit gene expression in the ovaries of immature female rats is stimulated by pregnant mare serum gonadotrophin. Biochemical and Biophysical Research Communications, 1986, 138, 1191-1195.	2.1	78
144	Estrogen Regulation of Kallikrein Gene Expression in the Rat Anterior Pituitary*. Endocrinology, 1986, 119, 268-273.	2.8	61

#	Article	IF	Citations
145	Elevated Plasma Levels of Pro-opiomelanocortin-Derived Peptides in Sheep following Hypothalamo-Pituitary Disconnection. Neuroendocrinology, 1986, 44, 508-514.	2.5	42
146	Arginine Vasopressin (AVP) and AVP-Like Immunoreactivity in Peripheral Tissues. Endocrine Reviews, 1986, 7, 449-460.	20.1	69
147	Localization of Arginine Vasopressin-Neurophysin II Messenger Ribonucleic Acid in the Hypothalamus of Control and Brattleboro Rats by Hybridization Histochemistry with a Synthetic Pentadecamer Oligonucleotide Probe*. Endocrinology, 1985, 116, 2366-2368.	2.8	59
148	STRESS, DOPAMINERGIC BLOCKADE AND MEDIAN EMINENCE-NEUROINTERMEDIATE LOBE CATECHOLAMINE DEPLETION: EFFECTS ON HYPOTHALAMIC, PITUITARY AND PLASMA IMMUNOREACTIVE ?-ENDORPHIN. Clinical and Experimental Pharmacology and Physiology, 1984, 11, 221-229.	1.9	4
149	Foot Shock Analgesia. Neuroendocrinology, 1982, 35, 236-241.	2.5	20
150	Naloxone, Adrenalectomy, and Steroid Replacement:Evidence against a Role for Circulating Î²-Endorphin in Food Intake*. Endocrinology, 1981, 108, 189-192.	2.8	26
151	Development of Anti-hLH Antibodies after Therapy with Posterior Pituitary Extract*. Journal of Clinical Endocrinology and Metabolism, 1978, 47, 1-8.	3.6	16